|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1998-7-30
|
|
pubmed:abstractText |
Transforming growth factor (TGF)-beta2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-beta2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-beta2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0028-3878
|
|
pubmed:author |
pubmed-author:AustinHH,
pubmed-author:CalabresiP APA,
pubmed-author:CarlinoJJ,
pubmed-author:Dhib-JalbutSS,
pubmed-author:FieldsN SNS,
pubmed-author:HanhamAA,
pubmed-author:LewisL NLN,
pubmed-author:MaloniH WHW,
pubmed-author:McFarlandH FHF,
pubmed-author:MooreJJ,
pubmed-author:RackeM KMK,
pubmed-author:TranquillL RLR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
289-92
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9674825-Adult,
pubmed-meshheading:9674825-Blood Urea Nitrogen,
pubmed-meshheading:9674825-Cerebrospinal Fluid,
pubmed-meshheading:9674825-Chronic Disease,
pubmed-meshheading:9674825-Female,
pubmed-meshheading:9674825-Glomerular Filtration Rate,
pubmed-meshheading:9674825-Humans,
pubmed-meshheading:9674825-Male,
pubmed-meshheading:9674825-Middle Aged,
pubmed-meshheading:9674825-Multiple Sclerosis,
pubmed-meshheading:9674825-Renal Circulation,
pubmed-meshheading:9674825-Transforming Growth Factor beta
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
|
|
pubmed:affiliation |
Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
